FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michele De Tursi

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Physiology

Co-author Network

Publications

TOP 3
Domenico Angelucci; Giampiero Ausili-Cefaro; Graziella Castrilli; Ettore Cianchetti; Pasquale Cioffi; Michele De Tursi; Antonino Grassadonia; Simona Grossi; Stefano Iacobelli; Laura Iezzi; Paolo Noccioli; Maria Teresa Scognamiglio; Nicola Tinari; Lucia Anna Ursini; Marinella Zilli; Clara Natoli
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice.
Emanuela Salvatorelli; Consiglia Carella; Antonella Colasante; Michele De Tursi; Stefano Iacobelli; Renato Massari; Pierantonio Menna; Giorgio Minotti
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.
Nicola Tinari; Marinella Zilli; Liborio Stuppia; Michele De Tursi; Antonino Grassadonia; Stefano Iacobelli; Clara Natoli
An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michele De Tursi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Domenico Angelucci; Giampiero Ausili-Cefaro; Graziella Castrilli; Ettore Cianchetti; Pasquale Cioffi; Michele De Tursi; Antonino Grassadonia; Simona Grossi; Stefano Iacobelli; Laura Iezzi; Paolo Noccioli; Maria Teresa Scognamiglio; Nicola Tinari; Lucia Anna Ursini; Marinella Zilli; Clara Natoli
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice.
Journal of cancer research and clinical oncology 2013;139(2):269-80.
2012: Emanuela Salvatorelli; Consiglia Carella; Antonella Colasante; Michele De Tursi; Stefano Iacobelli; Renato Massari; Pierantonio Menna; Giorgio Minotti
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(12):2365-73.
2012: Nicola Tinari; Marinella Zilli; Liborio Stuppia; Michele De Tursi; Antonino Grassadonia; Stefano Iacobelli; Clara Natoli
An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
Current cancer drug targets 2012;12(4):439-52.
2011: Marcello Di Nisio; Noemi Ferrante; Beatrice Feragalli; Michele De Tursi; Stefano Iacobelli; Franco Cuccurullo; Ettore Porreca
Arterial thrombosis in ambulatory cancer patients treated with chemotherapy.
Thrombosis research 2011;127(4):382-3.
2009: Alessandra Gennari; Michele De Tursi; Consiglia Carella; Enrico Ricevuto; Cinzia Orlandini; Antonio Frassoldati; Pierfranco Conte; Paolo Bruzzi; Stefano Iacobelli
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer.
Breast cancer research and treatment 2009;115(1):131-6.
2007: Ida Iurisci; tyvin rich; Francis Lévi; Pasquale F Innominato; Nicola Tinari; Luciana Irtelli; Michele De Tursi; Antonino Grassadonia; Stefano Iacobelli
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):e17-9.
2007: Clara Natoli; Ettore Cianchetti; Nicola Tinari; Domenico Angelucci; Antonino Grassadonia; M Zilli; Corrado Ficorella; Enrico Ricevuto; S Grossi; Michele De Tursi; C Carella; Anna Iolanda Rispoli; Stefano Iacobelli
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(6):1015-20.
2006: Corrado Ficorella; Enrico Ricevuto; Maria Francesca Morelli; R Morese; Katia Cannita; G Cianci; Giampiero Porzio; Zorika Christiana Di Rocco; Federica De Galitiis; Michele De Tursi; Nicola Tinari; Stefano Iacobelli; Piero Marchetti
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Oncology reports 2006;15(5):1345-50.
2004: Antonino Grassadonia; Nicola Tinari; Bruno Fiorentino; Koichi Suzuki; Minoru Nakazato; Michele De Tursi; Cesidio Giuliani; Giorgio Napolitano; dinah singer; Stefano Iacobelli; Leonard D Kohn
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides.
Endocrinology 2004;145(10):4728-36.
2000: Clara Natoli; M T Scognamiglio; M T Martino; Luciana Irtelli; Michele De Tursi; Ettore Cianchetti; E Mascitelli; Nicola Tinari; Stefano Iacobelli
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer.
Anticancer research 2000;20(2B):1253-6.